Respiratory Medicine
Volume 103, Issue 8 , Pages 1231-1238 , August 2009

Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease

  • Yuji Higashimoto

      Affiliations

    • Department of Respiratory Medicine and Allergology, Kinki University School of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-8511 Japan
    • Department of Rehabilitation Medicine, Kinki University School of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-8511 Japan
    • Corresponding Author InformationCorresponding author. Department of Respiratory Medicine and Allergology, Kinki University School of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-8511 Japan. Tel.: +81 72 366 0221; fax: +81 72 366 0206.
    • ,
  • Takuya Iwata

      Affiliations

    • Department of Internal Medicine, Wakayama Medical University Kihoku Hospital, 219 Myoji, Katsuragi-cho, Ito-gun, Wakayama Prefecture 649-7113, Japan
    • ,
  • Morihiro Okada

      Affiliations

    • Department of Internal Medicine, Wakayama Medical University Kihoku Hospital, 219 Myoji, Katsuragi-cho, Ito-gun, Wakayama Prefecture 649-7113, Japan
    • ,
  • Hiroaki Satoh

      Affiliations

    • Department of Internal Medicine, Wakayama Medical University Kihoku Hospital, 219 Myoji, Katsuragi-cho, Ito-gun, Wakayama Prefecture 649-7113, Japan
    • ,
  • Kanji Fukuda

      Affiliations

    • Department of Rehabilitation Medicine, Kinki University School of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-8511 Japan
    • ,
  • Yuji Tohda

      Affiliations

    • Department of Respiratory Medicine and Allergology, Kinki University School of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-8511 Japan

Received 7 July 2008 ,Accepted 25 January 2009.

References 

  1. Thomason MJ, Strachan DP. Which spirometric indices best predict subsequent death from chronic obstructive pulmonary disease?. Thorax. 2000;55:785–788
  2. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007;30:993–1013
  3. Minai OA, Benditt J, Martinez FJ. Natural history of emphysema. Proc Am Thorac Soc. 2008;5:468–474
  4. Ogawa E, Ruan J, Connett JE, Anthonisen NR, Pare PD, Sandford AJ. Transforming growth factor-beta1 polymorphisms, airway responsiveness and lung function decline in smokers. Respir Med. 2007;101:938–943
  5. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Pare PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med. 2001;163:469–473
  6. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347–360
  7. Wouters EF. The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J. 2006;27:877–879
  8. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574–580
  9. Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J. 2005;25:885–890
  10. Higashimoto Y, Yamagata Y, Taya S, Iwata T, Okada M, Ishiguchi T, et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: similarities and differences. Respirology. 2008;13:128–133
  11. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27:902–907
  12. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250–255
  13. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995–2004
  14. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276
  15. Matsuse T, Fukuchi Y, Matsui H, Sudo E, Nagase T, Orimo H. Effect of cigarette smoking on pulmonary function in each phenotype M of alpha-1-protease inhibitor. Chest. 1995;107:395–400
  16. Clark KD, Wardrobe-Wong N, Elliott JJ, Gill PT, Tait NP, Snashall PD. Cigarette smoke inhalation and lung damage in smoking volunteers. Eur Respir J. 1998;12:395–399
  17. Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol. 1982;33:379–387
  18. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002;166:1218–1224
  19. Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1179–1184
  20. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax. 2006;61:1037–1042
  21. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol. 2003;28:12–24
  22. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax. 2007;62:595–601
  23. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest. 2005;127:558–564
  24. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep. 2006;8:421–428
  25. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61:849–853
  26. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Cordoba-Lanus E, Muros de Fuentes M, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008;133:1336–1343
  27. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc. 2005;105:409–416
  28. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596–1600
  29. Fletcher C, Peto R, Tinker C, Speizer F. The natural history of chronic bronchitis and emphysema. New York: Oxford University Press; 1976;
  30. Burchfiel CM, Marcus EB, Curb JD, Maclean CJ, Vollmer WM, Johnson LR, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med. 1995;151:1778–1785
  31. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497–1505
  32. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 2003;138:969–973
  33. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58:937–941
  34. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760–765
  35. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:1207–1214
  36. Nakagawa M, Bondy GP, Waisman D, Minshall D, Hogg JC, van Eeden SF. The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocyte. Blood. 1999;93:2730–2737

PII: S0954-6111(09)00037-7

doi: 10.1016/j.rmed.2009.01.021

Respiratory Medicine
Volume 103, Issue 8 , Pages 1231-1238 , August 2009

Article Tools